From the Guidelines
Tirzepatide is not contraindicated in patients with previous cerebrovascular accidents (CVAs), but caution is advised due to limited evidence on its use in this population. When prescribing tirzepatide to patients with a history of CVA:
- Start at the lowest dose of 2.5 mg once weekly
- Monitor closely for any neurological symptoms or changes
- Gradually increase the dose as tolerated, up to a maximum of 15 mg once weekly It's essential to note that while tirzepatide is not contraindicated, patients with a history of CVA may be at higher risk for cardiovascular events, as suggested by studies on similar medications, such as GLP-1 agonists, which have shown to reduce stroke risk 1. Tirzepatide, a GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has shown potential cardiovascular benefits in clinical trials, although its specific effects on patients with a history of CVA are not well-established 1. Given the limited evidence on tirzepatide's use in patients with previous CVAs, it is crucial to consider individual patient factors and use the medication as part of a comprehensive treatment plan that includes lifestyle modifications and other appropriate therapies for stroke prevention.
From the Research
Tirzepatide Contraindications
- There is no direct evidence to suggest that tirzepatide is contraindicated in patients with previous cerebrovascular accidents (CVAs) 2, 3, 4, 5, 6.
Cardiovascular Safety
- Studies have shown that tirzepatide does not increase the risk of major cardiovascular events, including stroke, in patients with type 2 diabetes 3, 4, 5.
- A meta-analysis found that GLP-1 receptor agonists, including tirzepatide, reduce the risk of major adverse cardiovascular events and stroke in patients with type 2 diabetes 4.
- A pre-specified meta-analysis of randomized controlled trials found that tirzepatide did not increase the risk of major cardiovascular events, including stroke, in patients with type 2 diabetes 5.
Adverse Events
- Real-world data from the FDA Adverse Event Reporting System (FAERS) database found that tirzepatide was associated with various adverse events, including injection site pain, nausea, and diarrhea, but did not identify an increased risk of stroke or cerebrovascular accidents 6.